Cannabis 280E Tax Relief Could Change CPA Planning in 2026

Key Takeaways

• Section 280E has blocked cannabis businesses from deducting ordinary expenses like rent, payroll, and utilities.

• A new federal order moved certain state-regulated medical cannabis activity from Schedule I to Schedule III, opening the door to 280E relief for medical operators.

• Treasury and the IRS are expected to issue guidance on how transition relief works for the 2026 tax year.

• Retroactive refund claims remain risky because DOJ and IRS actions still show resistance to earlier-year deductions.

• CPAs should separate medical cannabis relief, adult-use cannabis exposure, and refund-position risk before advising clients.

Why This Matters for CPAs

Cannabis tax planning just moved out of the niche file.

For years, state-licensed cannabis operators could sell legally under state law, hire employees, lease storefronts, and operate like normal businesses. But because marijuana remained a Schedule I controlled substance under federal law, Section 280E blocked them from deducting ordinary business expenses.

The accounting problem

That meant many companies were not taxed like normal operating businesses. They were taxed closer to gross profit.

A new federal order moved certain state-regulated medical cannabis activity from Schedule I to Schedule III, effective April 28, 2026. That could remove 280E from part of the industry and force accountants, tax advisers, lenders, and investors to rethink the financial statements they have been reading for years.

How 280E Distorted Cannabis Financials

Section 280E was written in 1982 to stop drug traffickers from deducting business expenses. Once cannabis became legal in many states, the rule created a strange mismatch. A company could be legal in its state and still lose normal federal deductions because federal law treated the product differently.

The practical effect

A cannabis company might deduct cost of goods sold, but not ordinary expenses such as rent, payroll, marketing, insurance, or utilities. For a retailer or vertically integrated operator, that can turn a modest operating margin into a much larger federal tax burden.

The scale of the issue

According to GreenWave Advisors estimates cited by Forbes, the U.S. cannabis industry incurred roughly $9 billion in income tax expense tied to 280E from 2023 through 2025.

For the top eight multi-state operators, GreenWave estimated that removing 280E would have lifted 2025 net income by as much as 57%.

What Changed in 2026

The order signed in April 2026 moved certain state-regulated medical cannabis activity to Schedule III. It does not fully legalize marijuana federally. It does not automatically cover adult-use operators. It does not settle every refund claim already filed.

The key planning date

For calendar-year taxpayers, Treasury and IRS guidance is expected to include a transition rule for the taxable year that includes the effective date of the order. That makes January 1, 2026 the key date for many companies, at least for current-year planning.

The first CPA question

Is the client operating in medical cannabis, adult-use cannabis, or both? Are the expenses tied to activity that falls within the order? Is the company taking a current-year position only, or also trying to recover prior-year taxes?

Those are not small distinctions. They decide whether this is a normal tax planning project or a controversy file.

Refund Claims Are the Risky Part

The biggest trap is assuming rescheduling automatically opens the door to prior-year refunds.

Why prior years are different

Forbes noted that the Department of Justice filed suit against TerrAscend in May 2026 to recover an $8.36 million refund the IRS had issued after the company filed an amended 2020 return claiming business deductions.

DOJ argued that cannabis was still Schedule I in 2020, so 280E still applied for that year.

What that means for advisers

Cannabis operators have been filing amended returns in anticipation of relief. Some may have strong arguments. Others may be stretching. CPAs should treat retroactive claims as a separate risk decision, not a simple follow-on from the 2026 change.

A current-year deduction position and a prior-year refund claim are not the same conversation.

What CPAs Should Watch Now

IRS and Treasury guidance

The next step is guidance. The exact transition rule will matter, especially for mixed medical and adult-use businesses.

The June 29 hearing

CPAs should also watch the June 29 administrative hearing on broader rescheduling. If adult-use cannabis remains outside the immediate relief, the industry could split into two tax worlds. Medical operators may get relief while adult-use operators remain stuck with 280E.

Financial statement treatment

If tax expense drops, after-tax cash flow improves. If refund claims become more credible, uncertain tax positions may change. If adult-use remains excluded, companies may need clearer segmentation between eligible and non-eligible activities.

The Bottom Line

Cannabis 280E relief could become one of the most important tax developments of 2026 for a specific but fast-moving client base.

The mistake would be treating it as a simple tax break. It is really a reset of how cannabis businesses report profitability, cash flow, refund exposure, and tax risk.

For CPAs, the right posture is practical caution. Use the 2026 change where guidance supports it. Document the client’s medical versus adult-use exposure. Keep retroactive claims on a tighter review track. And do not assume the end of 280E is the same thing as the end of cannabis tax complexity.

FAQ

What is Section 280E?

Section 280E is a federal tax rule that blocks businesses trafficking in Schedule I or Schedule II controlled substances from deducting ordinary business expenses.

Why does cannabis rescheduling affect 280E?

If qualifying medical cannabis activity is moved to Schedule III, Section 280E may no longer block ordinary business deductions for that activity.

Does 280E relief apply to recreational cannabis?

Not automatically. The current change applies to certain state-regulated medical cannabis activity, while adult-use cannabis remains a separate issue.

Can cannabis companies file amended returns for old 280E taxes?

Some companies are trying, but prior-year refund claims remain disputed. DOJ and IRS actions show that retroactive relief is not settled.

What should CPAs do first?

Separate medical and adult-use activity, review expense allocation, wait for IRS guidance, and treat prior-year refund claims as higher-risk tax positions.